"Curecle, a New Drug Development Company Focused on Chronic Intractable Vascular Diseases"

[Asia Economy Reporter Hyungsoo Park] Kyobo Securities analyzed on the 4th that the possibility of developing a diabetic macular edema treatment by Curacle would influence the valuation of the company.

Researcher Jeonghyun Kim of Kyobo Securities introduced, "Curacle is a new drug development company focused on chronic intractable vascular diseases, aiming to develop third-generation vascular disease treatments."

He continued, "The largest shareholder, Kwon Younggeun, Chairman of Curacle's Board, has long researched basic new drug development in the vascular field," adding, "He has published numerous related papers in international academic journals and holds patents."

Researcher Kim explained, "They possess key compounds such as CU06-RE for diabetic macular edema, CU01 for diabetic nephropathy, and CU03 for wet age-related macular degeneration," and "They also have a vascular endothelial function blocker development platform (SOLVADYS) that enhances clinical success potential and compound scalability."

He stated, "The demand forecast dates are from the 7th to the 8th, and the expected listing date is in July," adding, "The anticipated market capitalization is between 267.3 billion and 333.9 billion KRW, with the planned public offering amount ranging from 42.7 billion to 53.3 billion KRW."

Researcher Kim analyzed, "The diabetic macular edema treatment CU06-RE entered Phase 1 clinical trials in the United States last February," and "It aims to enter Phase 2 next year." Furthermore, he emphasized, "It is known to have a high possibility of technology transfer to European pharmaceutical companies," and "Its mechanism blocks dysfunction of vascular endothelial cells and restores their function."

Researcher Kim also stated, "In beagle dog model experiments, superior efficacy was confirmed compared to the existing diabetic macular edema treatment, Eylea."